

Genocea Biosciences Investor Relations Department 100 Acom Park Drive, 5th Floor Cambridge, MA 02140 United States

Visit IR website ☐ Sign-up for Email alerts ☐

NASDAQ: GNCA	
Last Trade:	0.81
Trade Time:	4:00 PM ET Apr 23, 2018
Change:	-0.05 - (- 5.953%)
Day Range	0.81 - 0.88
52-Week Range	0.79 - 7.29
Volume	934,420

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Genocea aims to transform vaccine discovery and development to improve millions of lives. We use ATLAS™, our proprietary technology platform that rapidly identifies T cell antigens associated with protective immune responses in humans exposed to a pathogen. We have a pipeline of novel vaccine candidates that stimulate the T cell arm of the immune system, which is increasingly recognized as critical to generating protective immunity against a wide array of diseases. Genocea's pipeline includes clinical programs addressing genital herpes and pneumococcus and research efforts in... (more)

Stock Performance



Press Releases [View all]

Apr 18, 2018

Genocea Presents Data at AACR Annual

Meeting Further Highlighting Advantages of

ATLAS Platform in Identification of

Neoantigens over in silico Methods

Apr 9, 2018

Genocea to Present Data at Upcoming
AACR Annual Meeting Further Highlighting
ATLAS Platform Ability to Identify and
Characterize Neoantigens for Cancer
Vaccines

Mar 12, 2018

Genocea Appoints Narinder Singh as SVP
Pharmaceutical Sciences & Manufacturing

Mar 5, 2018

Genocea to Present at Two March Investor Conferences

Feb 15, 2018

Genocea Reports Fourth Quarter and Full-Year 2017 Financial Results

Financials [View all]

Fourth Quarter Financial Results

Feb 16, 2018

Annual Report (10-K)

Apr 21, 2017

Proxy Statement (DEF 14A)

Nov 3, 2017

Quarterly Report (10-Q)

Aug 9, 2017

Quarterly Report (10-Q)

May 5, 2017

Quarterly Report (10-Q)